-
-
Overview
-
Amikacin is semi-synthetic, broad-spectrum aminoglycoside antibiotic derived from its counterpart, Kanamycin A. Amikacin was patented in 1971 and came into commercial use in 1976. The presence of the amino-hydroxy-butyryl group prevents enzymatic modification of Amikacin at multiple positions. This renders Amikacin a more effective decontaminating agent, as microorganisms which develop resistance to other aminoglycosides remain susceptible to Amikacin. This also gives Amikacin a broader spectrum than the other aminoglycosides currently in use. Amikacin is one of the most common aminoglycosides in veterinary research. It is commonly used in antimicrobial susceptibility testing.
Amikacin is freely soluble in water.2) (A003)Please contact us at for specific academic pricing.
Background
Amikacin binds to the 30S ribosomal subunit (specifically the 16S rRNA and S12 protein) resulting in interference with the translational initiation complex and mRNA misreading, which leads to a faulty or nonexistent protein.
-
- Properties
- Applications
-
Overview